NXP800 yields neither severe thrombocytopenia, nor any responses.
ApexOnco Front Page
Recent articles
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
Paloma-3 data suggest subcutaneous Rybrevant might have an edge over the intravenous formulation.
The PD-1 x VEGF bispecific apparently bests Keytruda, but questions remain.
Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.
This weekend’s oncology conference will feature at least 30 different ADC projects.
Early release of petosemtamab’s ASCO data suggest that analysts’ bull case has been met.
An initial winner of the ASCO abstract reveal, Verastem drops a bombshell.
